Newsmeme!
Discover News you didn't know existed
There's a new movement in breast cancer, and the focus is on survivorship.
In-Depth From A.D.A.M. Treatment Making dietary adjustments starting about 14 days before a period may help some women with certain mild menstrual disorders, such as cramping.
Lila Nachtigall, MD, professor of obstetrics and gynecology and director of the Women's Wellness Program at NYU Langone Medical Center, was honored with the 2008 NAMS/Bayer HealthCare Pharmaceuticals Inc. ET/EPT Research Award late Friday during The North American Menopause Society's Annual Meeting in Orlando, Florida. This award was designed to recognize and acknowledge an individual whose body ...
FAIRMONT - With the alphabet soup of medical acronyms, knowing who's who and what's what is confusing for the average patient. "Have you thought about going on to get your LPN?" one person asked Shelley Brennan-Vuocolo, a certified family nurse practitioner at Fairmont Medical Center.
Breast cancer is the leading killer of women ages 35 to 54 worldwide. More than a million develop the disease without knowing it, and almost 500,000 women die from it every year.
AEterna Zentaris, a biopharmaceutical company, has entered the second stage of patient recruitment for its Phase II trial in ovarian cancer with AEZS-108, a luteinizing hormone-releasing hormone agonist linked to doxorubicin.
Confronting a new diagnosis can be frightening, and because research changes so often, confusing. Here are some questions you may not think to ask your doctor, along with notes on why they’re important.
A barbeque benefit for Carolyn Caraway will be held October 11, 2008 at 410 East Washington Street, in Kennett. There will be Boston Butts for $25, chickens for $8, ribs for $15, pork steaks for $8 and barbeque by the pound for $5.
Over 100 women attended the Silver Ribbon Foundation's inaugural event 'Silver Lining' to support New Zealand women living with a gynaecological cancer.
AEterna Zentaris Inc. , a global biopharmaceutical company focused on endocrine therapy and oncology, today reported that it has entered the second stage of patient recruitment for its Phase 2 trial in ovarian cancer with AEZS-108, a luteinizing hormone-releasing hormone agonist linked to doxorubicin.
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |